Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Sabina Signoretti, M.D.

Co-Author

This page shows the publications co-authored by Sabina Signoretti and Rupal Bhatt.
Connection Strength

1.843
  1. ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. Sci Transl Med. 2021 01 20; 13(577).
    View in: PubMed
    Score: 0.238
  2. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunol Res. 2021 02; 9(2):156-169.
    View in: PubMed
    Score: 0.235
  3. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2018 10; 16(5):341-348.
    View in: PubMed
    Score: 0.197
  4. Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget. 2017 Nov 28; 8(61):103428-103436.
    View in: PubMed
    Score: 0.190
  5. Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget. 2016 Jul 05; 7(27):41857-41869.
    View in: PubMed
    Score: 0.174
  6. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1158-64.
    View in: PubMed
    Score: 0.161
  7. Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clin Cancer Res. 2015 Apr 15; 21(8):1925-1934.
    View in: PubMed
    Score: 0.157
  8. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J Transl Med. 2011 Dec 21; 9:220.
    View in: PubMed
    Score: 0.127
  9. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One. 2011 Apr 29; 6(4):e19144.
    View in: PubMed
    Score: 0.121
  10. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. . 2010 Oct; 9(10):2793-802.
    View in: PubMed
    Score: 0.115
  11. A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model. Mol Ther Methods Clin Dev. 2018 Jun 15; 9:203-210.
    View in: PubMed
    Score: 0.049
  12. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 08; 14(4):304-313.e6.
    View in: PubMed
    Score: 0.042
  13. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb 01; 21(3):561-8.
    View in: PubMed
    Score: 0.039
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.